TOP Financial
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
TOP Financial Group Limited operates as a Hong Kong-based online brokerage, offering a diverse array of trading services to its clientele. The company facilitates transactions in both domestic and int...
Latest News
10 hours ago · prnewswire.com
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine CarcinomasSingle-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint IDE849 has demonstrated a 52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4% in 2L+ NEC Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026 SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of transformative therapies to address unmet medical needs in cancer, today announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in previously treated (2L+) neuroendocrine carcinomas (NEC).
4 days ago · businesswire.com
Sinclair Advances DINOCARE® Fuel Platform With TOP TIERTM + Approved GasolineSALT LAKE CITY--(BUSINESS WIRE)--Sinclair Oil (Sinclair), an HF Sinclair (NYSE and NYSE Texas, Inc.: DINO) brand, is taking the next step in its commitment to fuel quality with the rollout of Sinclair fuel with DINOCARE®, a TOP TIERTM+ approved gasoline, building on the TOP TIERTM approved gasoline customers know today. The transition to TOP TIERTM+ strengthens Sinclair's established DINOCARE® fuel platform with enhanced fuel quality and engine cleanliness benefits, giving drivers even more con.
4 days ago · globenewswire.com
Top Ships Announces Sale of Two Newbuilding MR Tankers for about $14.5 millionATHENS, Greece, Nov. 12, 2026 (GLOBE NEWSWIRE) -- TOP Ships Inc. (the “Company” or “TOP Ships”) (NYSE American: TOPS), an international owner and operator of modern, fuel-efficient “ECO” tanker vessels, announced today that it has entered into an agreement with Rubico Inc., a related party, to sell 100% of the issued and outstanding shares of two Marshall Islands companies (the “SPVs”), each of which is party to a shipbuilding contract with Guangzhou Shipyard International Company Limited and China Shipbuilding Trading Co., Ltd. for the construction of a 47,499 dwt chemical/product oil carrier (the “Newbuilding MR Tankers”). The Newbuilding MR Tankers are scheduled for delivery in the fourth quarter of 2028 and the fourth quarter of 2029, respectively.
6 days ago · marketbeat.com
What K+S Aktiengesellschaft (SDF) Said on Its Q3 Earnings CallK+S Aktiengesellschaft ETR: SDF narrowed its 2026 earnings guidance after reporting a modest decline in third-quarter EBITDA, as higher logistics and energy costs offset stronger prices and de-icing salt demand.
14 days ago · globenewswire.com
TOP Financial Group Limited Addresses Recent Unusual Fluctuations in Stock PriceHOUSTON, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) -- TOP Financial Group Limited (NASDAQ: TOP, “TOP” or the “Company”), a fast-growing online brokerage firm specializing in local and foreign equities, futures, and options products, today issued a statement addressing the recent unusual fluctuations in its stock price and provided updates on its strategic business developments.
19 days ago · prnewswire.com
AMERICAN WATER REPORTS SOLID THIRD QUARTER 2026 RESULTS; NARROWS 2026 EPS GUIDANCE TO TOP HALF OF RANGE; AFFIRMS LONG-TERM TARGETS; INITIATES STANDALONE 2027 EPS GUIDANCE, REFLECTING GROWTH OF 8%Third quarter 2026 GAAP earnings were $1.94 per share, compared to $1.94 per share in 2025; year-to-date 2026 GAAP earnings were $4.56 per share, compared to $4.47 per share in 2025 Third quarter 2026 adjusted (non-GAAP) earnings of $2.00 per share, compared to $1.89 per share in the same quarter in 2025 and year-to-date 2026 adjusted (non-GAAP) earnings of $4.63 per share, compared to $4.40 per share in the same period in 2025 2026 adjusted earnings per share (EPS) guidance range is narrowed to $6.07 to $6.12 from $6.02 to $6.12; long-term targets affirmed Initiating standalone 2027 earnings per share guidance range of $6.53 to $6.63 Significant regulatory execution YTD on several fronts, including in PA and NJ, with new rates in effect in Q3 2026 capital investment plan of $3.7 billion on track; approximately 81,000 customer connections added from acquisitions through September 30, which includes the Nexus Water systems Progress continues on proposed merger with Essential Utilities; three states have approved and settlements have been reached in Pennsylvania, North Carolina and Texas CAMDEN, N.J., Oct. 28, 2026 /PRNewswire/ -- American Water Works Company, Inc. (NYSE: AWK) today reported adjusted earnings for the quarter ended September 30, 2026, of $2.00 per share, compared to $1.89 per share for the same quarter in 2025, and $4.63 per share for the year-to-date period ended September 30, 2026, compared to $4.40 per share for the same period in 2025.
20 days ago · globenewswire.com
TOP Ships Inc. Announces $5.0 Million Private Placement of Senior Convertible Notes and WarrantsATHENS, Greece, Oct. 27, 2026 (GLOBE NEWSWIRE) -- TOP Ships Inc. (the “Company” or “TOP Ships,” “we” or “us”) (NYSE American: TOPS), an international owner and operator of modern, fuel-efficient “ECO” tanker vessels, today announced it has entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor (the “Holder”) to issue senior convertible notes (the “Notes”) in the aggregate principal amount of $5,555,555.56, bearing an original issue discount of 10% and warrants (the “Warrants”) to purchase common shares with an aggregate initial cash exercise price of $5,555,555.56 in a private placement. The Company expects to issue such Notes and Warrants on or about October 28, 2026 (the “First Tranche Closing”), subject to the satisfaction of customary closing conditions. The Company will receive gross proceeds of $5,000,000 at the First Tranche Closing.
20 days ago · globenewswire.com
TOP Ships Inc. Announces Reverse Stock SplitATHENS, Greece, Oct. 27, 2026 (GLOBE NEWSWIRE) -- TOP Ships Inc. (the "Company" or "TOP Ships") (NYSE American: TOPS), an international owner and operator of modern, fuel-efficient "ECO" tanker vessels, announced today that its board of directors (the “Board”) has determined to effect a 1 for 10 reverse stock split (the “Reverse Stock Split”) of the Company's issued common shares, par value $0.01 (the “Common Shares”), effective at the opening of trading on November 6, 2026 (the “Effective Date”).
24 days ago · gurufocus.com
TOP Financial Group Ltd (TOP) Shares Fall 5.2% -- GF Value Says Still OvervaluedOn October 23, 2026, TOP Financial Group Ltd (TOP) shares fell 5.2%, closing at $15.29. This decline comes after a year of significant volatility, with the stoc
25 days ago · prnewswire.com
IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas17.4-month median OS in 2L SCLC (n=51) and 14.7-month median OS in 2L + ≥3L SCLC (n=101) 72.5% (37/51) ORR and 60.8% (31/51) cORR in 2L SCLC with 6.9-month median PFS; 68.3% (69/101) ORR and 54.5% (55/101) cORR in 2L + ≥3L SCLC with 6.8-month median PFS 76.9% (20/26) ORR and 65.4% (17/26) cORR in SCLC patients with brain metastases Efficacy observed in NECs, with 52.6% (10/19) ORR, 36.8% (7/19) cORR, 7.0-month median PFS and an 82.4% nine-month OS rate Grade ≥3 TRAE of 33.3% at the 2.4 mg/kg expansion dose. 2.5% treatment-related discontinuation rate and 0.8% Grade ≥3 ILD rate observed across the study (n=122) In IDEAYA's separate IDE849 global clinical study at the 2.4 mg/kg and 3.5 mg/kg expansion doses a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) have been observed, respectively Following successful Type C meetings with the U.S. FDA, IDEAYA is targeting to initiate two Phase 3 registrational trials with IDE849 in ES-SCLC and NEC.
Add to Watchlist
Select watchlists to add or remove TOP